

Ilse Schwarzinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557254/publications.pdf>

Version: 2024-02-01

32
papers

414
citations

840776

11
h-index

794594

19
g-index

33
all docs

33
docs citations

33
times ranked

1015
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
3	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	3.4	38
4	Mortality in patients resuscitated from out-of-hospital cardiac arrest based on automated blood cell count and neutrophil lymphocyte ratio at admission. <i>Resuscitation</i> , 2017, 116, 49-55.	3.0	37
5	Performance Evaluation of the Sysmex XE-5000 Hematology Analyzer for White Blood Cell Analysis in Cerebrospinal Fluid. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 194-198.	2.5	29
6	The TGF β /SOX4 axis and ROS-driven autophagy co-mediate CD39 expression in regulatory T cells. <i>FASEB Journal</i> , 2020, 34, 8367-8384.	0.5	28
7	Lysis matters: Red cell lysis with FACS Lyse affects the flow cytometric enumeration of circulating leukemic blasts. <i>Journal of Immunological Methods</i> , 2013, 390, 127-132.	1.4	19
8	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.9	18
9	<i>in vitro</i> and <i>in vivo</i> effects of JAK2 inhibition in chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 562-567.	2.2	13
10	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.4	12
11	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression <i>in vitro</i> . <i>Frontiers in Immunology</i> , 2019, 10, 1790.	4.8	12
12	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	4.1	11
13	Impaired efferocytosis by monocytes in multiple myeloma. <i>Oncology Letters</i> , 2018, 16, 409-416.	1.8	9
14	Attenuation of canonical NF κ B signaling maintains function and stability of human Treg. <i>FEBS Journal</i> , 2021, 288, 640-662.	4.7	9
15	Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients. <i>Npj Vaccines</i> , 2020, 5, 67.	6.0	8
16	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	3.8	7
17	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 404-410.	1.9	4
18	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. <i>Annals of Hematology</i> , 2020, 99, 2599-2609.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib. <i>British Journal of Haematology</i> , 2018, 181, 431-431.	2.5	3
20	The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 137-139.	2.5	3
21	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , 2014, 124, 2859-2859.	1.4	3
22	Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. <i>Haematologica</i> , 2016, 101, e492-e492.	3.5	1
23	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	1.8	1
24	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
25	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
26	NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML. <i>Blood</i> , 2021, 138, 3435-3435.	1.4	1
27	Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O176-O180.	1.3	0
28	The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL. <i>Blood</i> , 2005, 106, 1221-1221.	1.4	0
29	Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes. <i>Blood</i> , 2006, 108, 4828-4828.	1.4	0
30	Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation. <i>Blood</i> , 2016, 128, 3189-3189.	1.4	0
31	High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis. <i>Blood</i> , 2016, 128, 5503-5503.	1.4	0
32	Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 4269-4269.	1.4	0